<DOC>
	<DOCNO>NCT01175655</DOCNO>
	<brief_summary>The primary aim study establish safety infusion Mesenchymal Stromal Cells ( MSC ) relate unrelated Human Leukocyte Antigen ( HLA ) identical HLA mismatch donor management bronchiolitis obliterans syndrome lung transplantation .</brief_summary>
	<brief_title>A Study Evaluate Potential Mesenchymal Stromal Cells Treat Obliterative Bronchiolitis After Lung Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<criteria>1 . Patients single , bilateral heartlung allograft 2 . Patients bronchiolitis obliterans syndrome ( BOS ) grade 2 &amp; 3 ( define grade accord international criterion ( Appendix 1 ) ) , evidence deterioration allograft function ( i.e . deteriorate FEV1 worsen BOS grade ) within last 12 month . 3 . Patients BOS grade 1 evidence deterioration allograft function ( i.e . deteriorate FEV1 worsen BOS grade ) within last 12 month least one follow additional risk factor subsequent death : Single lung transplant Rapid deterioration ( &gt; 20 % fall FEV1 previous 12 month ) A pretransplant diagnosis usual interstitial pneumonia ( pulmonary fibrosis ) pulmonary hypertension 1 . Patients active infection , acute allograft rejection , airway anastomotic complication 2 . Patients &gt; 3 infective exacerbation BOS last 12 month 3 . Patients history cytomegalovirus ( CMV ) pneumonitis 4 . Patients poor performance status and/or expect survive 3 month 5 . Patients pregnant breastfeed 6 . Patients allergy beef product . 7 . Any condition opinion Investigator may interfere safety patient , / completion require followup visit evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mesenchymal stromal cell</keyword>
	<keyword>Bronchiolitis obliterans</keyword>
	<keyword>Lung transplant</keyword>
</DOC>